Influence of type-I Interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 3, 2014, Pages 492-502

  Booy, Stephanie ^a   van Eijck, Casper H J ^a   Dogan, Fadime ^a   van Koetsveld, Peter M ^a   Hofland, Leo J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anti cancer effects; IFNAR 1; IFNAR 2c; Pancreatic cancer; Type I interferons

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; ALPHA INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; BETA1A INTERFERON; IFNAR1 PROTEIN, HUMAN; IFNAR2 PROTEIN, HUMAN; MESSENGER RNA; RECOMBINANT PROTEIN;

APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IC50; METABOLISM; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; INTERFERON BETA-1A; INTERFERON-ALPHA; INTERFERON-BETA; PANCREATIC NEOPLASMS; RECEPTOR, INTERFERON ALPHA-BETA; RECOMBINANT PROTEINS; RNA, MESSENGER;

EID: 84894555725     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12200     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350: 1200-10.
3. Thomas A, Dajani K, Neoptolemos JP, et al. Adjuvant therapy in pancreatic cancer. Dig Dis. 2010; 28: 684-92.
4. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297: 267-77.
5. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999; 230: 776-82.
6. Linehan DC, Tan MC, Strasberg SM, et al. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study. Ann Surg. 2008; 248: 145-51.
7. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2003; 185: 476-80.
8. Nukui Y, Picozzi VJ, Traverso LW. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2000; 179: 367-71.
9. Pestka S, Langer JA, Zoon KC, et al. Interferons and their actions. Annu Rev Biochem. 1987; 56: 727-77.
10. Wagner TC, Velichko S, Chesney SK, et al. Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors. Int J Cancer. 2004; 111: 32-42.
11. Morak MJ, van Koetsveld PM, Kanaar R, et al. Type I interferons as radiosensitisers for pancreatic cancer. Eur J Cancer. 2011; 47: 1938-45.
12. Bekisz J, Schmeisser H, Hernandez J, et al. Human interferons alpha, beta and omega. Growth Factors. 2004; 22: 243-51.
13. Domanski P, Colamonici OR. The type-I interferon receptor. The long and short of it. Cytokine Growth Factor Rev. 1996; 7: 143-51.
14. Parmar S, Platanias LC. Interferons: mechanisms of action and clinical applications. Curr Opin Oncol. 2003; 15: 431-9.
15. Wang BX, Rahbar R, Fish EN. Interferon: current status and future prospects in cancer therapy. J Interferon Cytokine Res. 2011; 31: 545-52.
16. Rudick RA, Goelz SE. Beta-interferon for multiple sclerosis. Exp Cell Res. 2011; 317: 1301-11.
17. Vitale G, van Eijck CH, van Koetsveld Ing PM, et al. Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann Surg. 2007; 246: 259-68.
18. Jost E, Roos WP, Kaina B, et al. Response of pancreatic cancer cells treated with interferon-alpha or beta and co-exposed to ionising radiation. Int J Radiat Biol. 2010; 86: 732-41.
19. Saidi RF, Ahad A, Tilak J, et al. The expression of interferon receptor alpha/beta in human pancreatic cancer in nude mice is essential for tumor response to interferon alpha treatment. J Surg Res. 2012; 173: 309-13.
20. Saidi RF, Williams F, Silberberg B, et al. Expression of interferon receptors in pancreatic cancer: identification of a novel prognostic factor. Surgery. 2006; 139: 743-8.
21. Solorzano CC, Hwang R, Baker CH, et al. Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. Clin Cancer Res. 2003; 9: 1858-67.
22. Tomimaru Y, Eguchi H, Wada H, et al. Synergistic antitumor effect of interferon-ss with gemcitabine in interferon-alpha-non-responsive pancreatic cancer cells. Int J Oncol. 2011; 38: 1237-43.
23. Hofland LJ, van Koetsveld PM, Lamberts SW. Percoll density gradient centrifugation of rat pituitary tumor cells: a study of functional heterogeneity within and between tumors with respect to growth rates, prolactin production and responsiveness to the somatostatin analog SMS 201-995. Eur J Cancer. 1990; 26: 37-44.
24. van Koetsveld PM, Vitale G, de Herder WW, et al. Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. J Clin Endocrinol Metab. 2006; 91: 4537-43.
25. De Martino MC, van Koetsveld PM, Feelders RA, et al. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells. Endocr Relat Cancer. 2012; 19: 351-64.
26. Vitale G, de Herder WW, van Koetsveld PM, et al. IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro. Cancer Res. 2006; 66: 554-62.
27. Gukovskaya AS, Perkins P, Zaninovic V, et al. Mechanisms of cell death after pancreatic duct obstruction in the opossum and the rat. Gastroenterology. 1996; 110: 875-84.
28. Novick D, Cohen B, Rubinstein M. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell. 1994; 77: 391-400.
29. Constantinescu SN, Croze E, Murti A, et al. Expression and signaling specificity of the IFNAR chain of the type I interferon receptor complex. Proc Natl Acad Sci USA. 1995; 92: 10487-91.
30. Picozzi VJ, Abrams RA, Decker PA, et al. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol. 2011; 22: 348-54.
31. Schmidt J, Abel U, Debus J, et al. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol. 2012; 30: 4077-83.
32. Saidi RF, Remine SG, Jacobs MJ. Interferon receptor alpha/beta is associated with improved survival after adjuvant therapy in resected pancreatic cancer. HPB (Oxford). 2007; 9: 289-94.
33. Saidi RF, Williams F, Ng J, et al. Interferon receptors and the caspase cascade regulate the antitumor effects of interferons on human pancreatic cancer cell lines. Am J Surg. 2006; 191: 358-63.
34. Bekisz J, Baron S, Balinsky C, et al. Antiproliferative properties of type I and type II interferon. Pharmaceuticals (Basel). 2010; 3: 994-1015.
35. Deer EL, Gonzalez-Hernandez J, Coursen JD, et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 2010; 39: 425-35.
36. Shang D, Ito N, Watanabe J, et al. Synergy of interferon-alpha and 5-fluorouracil in human renal cell carcinoma requires p53 activity. Eur Urol. 2007; 52: 1131-9.
37. Johns TG, Mackay IR, Callister KA, et al. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta. J Natl Cancer Inst. 1992; 84: 1185-90.
38. Der SD, Zhou A, Williams BR, et al. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA. 1998; 95: 15623-8.
39. de Weerd NA, Vivian JP, Nguyen TK, et al. Structural basis of a unique interferon-beta signaling axis mediated via the receptor IFNAR1. Nat Immunol. 2013; 14: 901-7.
40. Caraglia M, Dicitore A, Marra M, et al. Type I interferons: ancient peptides with still under-discovered anti-cancer properties. Protein Pept Lett. 2013; 20: 412-23.
41. Caraglia M, Marra M, Tagliaferri P, et al. Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr Cancer Drug Targets. 2009; 9: 690-704.
42. Buchwalder PA, Buclin T, Trinchard I, et al. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res. 2000; 20: 857-66.
43. Hu X, Miller L, Richman S, et al. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol. 2012; 52: 798-808.
44. Mager DE, Neuteboom B, Jusko WJ. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys. Pharm Res. 2005; 22: 58-61.
45. Dunn GP, Bruce AT, Sheehan KC, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol. 2005; 6: 722-9.